期刊
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
卷 18, 期 14, 页码 5554-5574出版社
IVYSPRING INT PUBL
DOI: 10.7150/ijbs.71449
关键词
hepatoid adenocarcinoma of the stomach; liver metastasis; prognosis; whole-exome sequencing; clinicogenomic landscape
资金
- Zhejiang Science and Technology Planning Project [2021C03119]
- Key Research and Development Program of Science and Technology Department of Zhejiang Province [2018C03022]
- National Natural Science Foundation of China [81803107]
- Natural Science Foundation of Zhejiang Province [LQ20H160043]
- Project of the Regional Diagnosis and Treatment Centre of the Health Planning Committee [JBZX-201903]
This study revealed the poor prognosis and high risk of liver metastasis in patients with hepatoid adenocarcinoma of the stomach (HAS). By comparing genomic data, the researchers identified a genomic landscape associated with unfavorable clinical features in HAS and potential therapeutic targets. These findings lay the foundations for precise diagnosis and therapy for this rare but lethal disease.
Hepatoid adenocarcinoma of the stomach (HAS) is a rare subtype of gastric cancer (GC) that histologically resembles hepatocellular carcinoma (HCC). Despite its low incidence, HAS had a poor 5-year survival rate. Currently, the linkages between clinicopathological and genomic features of HAS and its therapeutic targets remain largely unknown. Herein, we enrolled 90 HAS patients and 270 stage-matched non-HAS patients from our institution for comparing clinicopathological features. We found that HAS had worse overall survival and were more prone to develop liver metastasis than non-HAS in our cohort, which was validated via meta-analysis. By comparing whole-exome sequencing data of HAS (n=30), non-HAS (n=63), and HCC (n=355, The Cancer Genome Atlas), we identified a genomic landscape associated with unfavorable clinical features in HAS, which contained frequent somatic mutations and widespread copy number variations. Notably, signaling pathways regulating pluripotency of stem cells affected by frequent genomic alterations might contribute to liver metastasis and poor prognosis in HAS patients. Furthermore, HAS developed abundant multiclonal architecture associated with liver metastasis. Encouragingly, target analysis suggested that HAS patients might potentially benefit from anti-ERBB2 or anti-PD-1 therapy. Taken together, this study systematically demonstrated a high risk of liver metastasis and poor prognosis in HAS, provided a clinicogenomic landscape underlying these unfavorable clinical features, and identified potential therapeutic targets, laying the foundations for developing precise diagnosis and therapy in this rare but lethal disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据